This is a England news story, published by Guardian, that relates primarily to trastuzumab deruxtecan news.
For more England news, you can click here:
more England newsFor more trastuzumab deruxtecan news, you can click here:
more trastuzumab deruxtecan newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Guardian, you can click here:
more news from GuardianOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
advanced breast cancer. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest invasive breast cancers news, breast cancer news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
breast cancersGuardian
•68% Informative
Enhertu has been rolled out to patients with HER2-low breast cancer in Scotland and Northern Ireland .
But the National Institute for Health and Care Excellence (Nice ) has rejected it for patients in England .
Women in Wales are also being denied the drug, also known as trastuzumab deruxtecan .
Compelling evidence suggests the treatment can increase the amount of time patients live and give them more time before their disease progresses.
The treatment was blocked for NHS use in England in March . Nice said the cost the NHS was being asked to pay for Enhertu was “too high” in relation to its benefits. A quarter of a million people have signed a petition calling for an “urgent solution” to get the treatment to women living with secondary breast cancer as soon as possible..
VR Score
69
Informative language
68
Neutral language
59
Article tone
semi-formal
Language
English
Language complexity
53
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links